CJC-1295 compounded vs brand name: what you're actually buying

Last updated 2026-07-30

Is there an FDA-approved brand name version of CJC-1295?

No. This is the first thing to get straight before spending money. CJC-1295 has never gone through FDA new drug approval, and no company sells it as an approved prescription brand the way Genotropin or Norditropin are approved brand names for recombinant human growth hormone ^[1]. What exists instead is a patent and published research literature. CJC-1295 was developed by a Canadian biotech, ConjuChem, and described in a 2005 Journal of Clinical Endocrinology & Metabolism study as a long-acting growth-hormone-releasing factor analog covalently bound to a drug affinity complex, hence "DAC" ^[2]. ConjuChem's clinical program stalled, and the compound never reached market as an approved drug for any indication. So when you see "brand name CJC-1295" advertised anywhere, that is marketing language, not a regulatory fact. There is no NDC-listed, FDA-approved product to compare against. Every legal, quasi-legal, and gray-market version you can find is some form of compounded or bulk research peptide. The real question isn't compounded vs. brand. It's regulated compounding vs. unregulated sourcing, and that's the distinction this article actually answers.

What does "compounded CJC-1295" mean in practice?

Compounded means a licensed pharmacy (or, less reassuringly, an unlicensed supplier calling itself a lab) mixes or reconstitutes the peptide into a dosage form, usually a sterile injectable vial, based on a formula rather than a mass-manufactured, FDA-approved product. Legitimate pharmacy compounding in the U.S. happens under two federal frameworks. Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional compounding pharmacies that prepare patient-specific prescriptions ^[3]. Section 503B covers "outsourcing facilities" that can compound in larger batches without a patient-specific prescription, but must register with the FDA and follow current good manufacturing practice (cGMP) rules ^[4]. Facilities that meet 503B and choose to register are inspected by the FDA on a risk-based schedule. Here's the catch specific to CJC-1295: the FDA maintains a list of bulk drug substances that outsourcing facilities are allowed to use, and growth-hormone-releasing peptides have been a recurring subject of FDA warning letters and import alerts, not blanket approval. In 2023 the FDA sent warning letters to multiple compounders over sale of unapproved GHRH-analogue and GHRP peptides, including CJC-1295 and ipamorelin, stating these substances lack an adequate basis for compounding under sections 503A and 503B ^[5]. That doesn't mean no pharmacy can legally handle it under any circumstance, but it does mean the regulatory footing is genuinely unsettled, not a rubber stamp.

CJC-1295 with DAC vs without DAC: what's actually different?

This is the single most important technical distinction in the CJC-1295 world, and it has nothing to do with brand vs. compounded. It's a molecular difference. CJC-1295 with DAC has the drug affinity complex attached, which lets it bind reversibly to albumin in the blood. That binding is what gives it a long half-life. The 2005 clinical study measured a half-life of approximately 5.8 to 8.1 days after single doses in humans, and found that repeated dosing produced sustained elevation of GH and IGF-1 for multiple days between injections ^[2]. CJC-1295 without DAC (often sold as "Mod GRF 1-29") is the same core amino acid sequence, minus the DAC tail. Without that albumin-binding piece, it behaves like a fast, short pulse. Its half-life is measured in minutes, commonly cited in the pharmacology literature on GHRH analogs as roughly 30 minutes or less, similar to native GHRH's short half-life of only a few minutes ^[6]. The practical consequence: DAC versions are marketed for less frequent dosing (every 3 to 7 days in various protocols) because of the sustained blood level, while no-DAC versions are used for once or twice daily dosing timed around a GH pulse. Neither version has an FDA-approved dosing schedule, because neither is an approved drug. Anything you read about "the standard protocol" is a convention that spread through forums and compounder marketing, not a dose established in a regulatory trial. If you're comparing sources, confirm which molecule you're actually being sold. Sellers sometimes use "CJC-1295" loosely to mean either version, and that ambiguity alone should make you cautious.

Why is CJC-1295 usually paired with ipamorelin, and is that combination studied?

The rationale is mechanistic, not a proven clinical outcome. CJC-1295 is a GHRH analog: it acts on the GHRH receptor in the pituitary to encourage growth hormone release. Ipamorelin is a ghrelin-receptor agonist (a GH secretagogue in the GHRP family): it acts on a different receptor to also stimulate GH release, largely without the cortisol and prolactin elevation seen with older secretagogues like GHRP-6, based on the original ipamorelin characterization studies in the 1990s ^[7]. Because they hit two different receptors, the argument (again, mechanistic reasoning, not a head-to-head human outcomes trial of the combination) is that combining them produces a bigger, more synergistic GH pulse than either alone. This idea comes from older GH secretagogue pharmacology work showing that GHRH and ghrelin-mimetic compounds act on separate pathways and can produce additive GH release when combined in controlled research settings ^[8]. What's missing is a large, published clinical trial of CJC-1295 plus ipamorelin specifically, at defined doses, with hard outcomes like lean mass, fracture risk, or mortality. What exists is basic pharmacology on each individual compound, some of it decades old, and a mountain of anecdotal protocol-sharing on bodybuilding and biohacking forums. That forum material is not evidence. It can be a reasonable source of practical experience, but it should never be mistaken for a controlled study, and it very often isn't. If you want a fuller breakdown of what the actual peer-reviewed evidence says (as opposed to the folklore), the CJC-1295 reviews page and the CJC-1295 pros and cons page both go deeper into that evidence-vs-anecdote line.

Compounded vs gray-market research chemical: what's the real difference?

This is the comparison that actually matters, more than compounded-vs-brand. On one side you have compounding pharmacies operating (at least nominally) under 503A or 503B of the FDCA, subject to state board of pharmacy licensing and, for 503B facilities, FDA registration and inspection ^[3][4]. On the other side you have unlicensed sellers, often overseas, shipping vials labeled "not for human consumption" or "research use only" with no pharmacy license, no batch-level purity testing disclosed to the buyer, and no legal accountability if the vial is contaminated or mislabeled. | Feature | Licensed compounding pharmacy | Gray-market "research" seller |

How do prices compare between compounded and unregulated sources?

There's no single market price for CJC-1295 because it isn't sold as a mass-market approved drug with published wholesale pricing. What you'll see instead is a wide range depending on dose per vial, whether it includes DAC, and whether it's sold through a pharmacy-adjacent telehealth channel or a straight research-chemical storefront. As a rough market observation (not a price you should treat as fixed, since this segment changes fast and isn't regulated), vials in the 2mg to 5mg range commonly run somewhere in the tens of dollars to over a hundred dollars each on research-chemical sites, with compounded pharmacy channels typically pricing higher once a consultation or prescription-adjacent service is bundled in. Because none of this is FDA-approved pricing data, treat any specific number you see, including ranges quoted elsewhere online, with real skepticism, and get a current quote directly rather than assuming yesterday's price holds. What you should not do is treat "cheaper" as a selling point on its own. A rock-bottom price from an unlicensed overseas vendor is more often a signal of no quality control than a bargain.

Is it legal to buy CJC-1295, and does that change by source?

This is genuinely unsettled, and anyone who tells you it's simple is oversimplifying. CJC-1295 is not scheduled as a controlled substance under the federal Controlled Substances Act. But "not scheduled" doesn't mean "approved for sale." The FDA's position, stated in warning letters issued to compounders in 2023, is that GHRH-analogue and GH-secretagogue peptides including CJC-1295 and ipamorelin lack sufficient safety and efficacy data to be legally compounded under existing bulk substance rules, and that marketing them for anti-aging or bodybuilding use runs afoul of the FDCA's new drug provisions ^[5]. Separately, growth hormone and related substances carry sport-specific restrictions. The World Anti-Doping Agency lists growth hormone releasing factors, including GHRH analogs like CJC-1295, as prohibited substances under class S2 of the WADA Prohibited List, which matters directly if you're a tested athlete at any level ^[9]. For most non-competitive buyers, the practical legal risk sits less with personal possession and more with how a seller is marketing and shipping the product, and whether a pharmacy is complying with 503A/503B rules. That's exactly why the sourcing channel matters more here than in most supplement or drug purchases you'll ever make.

What quality checks actually separate a trustworthy source from a risky one?

A few concrete things to ask for, none of which cost you anything to request. First, ask whether the pharmacy is licensed by a state board of pharmacy and, if it claims 503B outsourcing status, whether it's on the FDA's registered outsourcing facility list ^[4]. That list is public. Second, ask for a current certificate of analysis specific to the lot you're buying, not a generic PDF from a prior batch. Third, check whether the product requires any clinician review before dispensing. A source willing to ship a peptide with zero medical intake, zero dose guidance beyond a forum-sourced protocol, and no lot-specific testing is telling you something about how seriously it takes safety. None of these checks turn an unapproved compound into an approved drug. They just tell you whether you're dealing with an operation that behaves like a real pharmacy or one that behaves like a chemical importer with a website. That gap is where almost all the real-world risk in this category actually lives, more than the DAC vs. no-DAC molecular question people obsess over.

What does the actual evidence say about CJC-1295's effects, separate from marketing claims?

The core human data is thinner than the marketing around it suggests. The primary clinical reference remains the 2005 study in the Journal of Clinical Endocrinology & Metabolism, which tested CJC-1295 with DAC in healthy adults and reported sustained increases in GH and IGF-1 levels after single and repeated doses, with the authors noting good tolerability in that limited trial population ^[2]. That is a real, peer-reviewed finding. What it is not: a large trial, a long-term safety study, an approved dosing regimen, or evidence for the specific bodybuilding and anti-aging outcomes (fat loss, muscle gain, skin quality, longevity) that dominate marketing copy. Those downstream claims are extrapolated from the fact that GH and IGF-1 went up, combined with general endocrinology knowledge about what GH does in the body, not from a trial that actually measured those endpoints in CJC-1295 users. If you want the fuller picture of what's documented versus what's inferred, the CJC-1295 results timeline and CJC-1295 success rate pages walk through the timeline and honest limits of that evidence in more depth. The short version for this article: treat any specific before-and-after claim you see (including the ones on forums) as an individual anecdote, not a study finding.

So which should I choose: compounded through a pharmacy, or a research-chemical vial?

If you've decided to proceed despite the unsettled regulatory picture, the compounded-pharmacy route is the more defensible choice, not because it's approved (it isn't) but because it comes with actual oversight layers a gray-market vial doesn't. A licensed compounding pharmacy operating under 503A or 503B has a state board looking over its shoulder and, for 503B facilities, FDA registration and periodic inspection ^[3][4]. A telehealth-adjacent model that includes a clinician review before dispensing adds another layer most research-chemical sellers skip entirely. None of that makes the underlying substance FDA-approved, and none of it substitutes for a doctor who knows your health history weighing in on whether this makes sense for you at all. This is also the point where naming a concrete path is more useful than staying abstract: CJC-1295 Co reviews provider-reviewed sourcing routes and, where a reader is ready to move forward, points to a fulfilling pharmacy partner that operates under that pharmacy-oversight model rather than an unregulated import channel. That's a meaningfully different starting point than ordering a vial from a site with no license number anywhere on it. Before you commit, it's worth reading the honest case for and against use in the first place. The is CJC-1295 worth it page and the CJC-1295 before and after page both lay out realistic expectations rather than marketing ones.

Frequently asked questions

Is there a real brand-name version of CJC-1295?

No. CJC-1295 has never received FDA approval as a prescription drug, so there's no approved brand name to compare against. Every product sold, whether through a compounding pharmacy or a research-chemical site, is an unapproved preparation. Marketing language calling something "brand name CJC-1295" is not a regulatory designation, it's a sales phrase.

What's the difference between CJC-1295 with DAC and without DAC?

DAC (drug affinity complex) lets the molecule bind albumin in blood, extending its half-life to roughly 5.8 to 8.1 days per the original 2005 clinical study, versus a half-life of around 30 minutes or less for the no-DAC version (often sold as Mod GRF 1-29). DAC versions are dosed less often; no-DAC versions are dosed daily around a GH pulse.

Is compounded CJC-1295 legal to buy in the U.S.?

It's unsettled. CJC-1295 isn't a scheduled controlled substance, but the FDA issued warning letters in 2023 stating that GHRH-analogue peptides like CJC-1295 lack an adequate basis for legal compounding under sections 503A and 503B of the FDCA. Legality largely hinges on how a specific seller is marketing and dispensing it, not on personal possession alone.

Why is CJC-1295 combined with ipamorelin instead of used alone?

CJC-1295 acts on the GHRH receptor; ipamorelin acts on the separate ghrelin receptor. Basic pharmacology on GH secretagogues suggests combining agents on two different receptors can produce a bigger GH pulse than either alone. There is no large published trial of this exact combination measuring hard outcomes, so treat the rationale as mechanistic, not proven.

Are research-chemical CJC-1295 vials the same product as pharmacy-compounded ones?

Not necessarily. Both may contain the same peptide sequence, but a licensed compounding pharmacy operates under state board oversight and, for 503B facilities, FDA registration and inspection. A research-chemical vial typically has no license, no verified sterility testing, and is explicitly labeled not for human use, regardless of what the marketing implies.

How much does CJC-1295 typically cost?

Pricing varies widely and isn't standardized, since it's not sold as an FDA-approved drug with published wholesale rates. Vials commonly range from roughly tens of dollars to over a hundred dollars depending on dose, DAC status, and channel. Because this market shifts constantly and is unregulated, get a direct current quote rather than relying on any fixed number.

Does CJC-1295 show up on doping tests?

Yes, for tested athletes. The World Anti-Doping Agency lists growth hormone releasing factors, which includes GHRH analogs like CJC-1295, as prohibited under class S2 of its Prohibited List. Anyone competing under WADA or an affiliated body's rules should treat this as a banned substance, not a supplement gray area.

Can I check if a compounding pharmacy is actually licensed?

Yes. State boards of pharmacy maintain public license lookup tools, and the FDA publishes a list of registered 503B outsourcing facilities. Before buying, ask the seller directly which category they operate under and verify the license or registration yourself rather than taking their word for it.

Is CJC-1295 with DAC stronger or better than without DAC?

Neither is simply "stronger." DAC gives a sustained, lower-amplitude elevation in GH and IGF-1 over days; no-DAC gives a sharper, short-lived pulse meant to mimic natural GH release timing. Which is preferable depends on the goal and dosing schedule someone is following, and neither has an FDA-established optimal protocol.

What evidence actually supports CJC-1295's effects on GH and IGF-1?

The main human data comes from a 2005 study in the Journal of Clinical Endocrinology & Metabolism, which found CJC-1295 with DAC produced sustained increases in GH and IGF-1 after single and multiple doses in healthy adults. It's a real, peer-reviewed finding, but it's a small trial and doesn't establish long-term safety or body-composition outcomes.

What questions should I ask before buying from any CJC-1295 source?

Ask if the pharmacy is state-licensed or FDA-registered as a 503B outsourcing facility, request a lot-specific certificate of analysis, and ask whether a clinician reviews your case before dispensing. A source that can't answer these plainly is behaving like an unregulated chemical importer, not a pharmacy.

Should I trust bodybuilding forum protocols for dosing CJC-1295?

Treat them as anecdote, not evidence. Forum protocols for dose, frequency, and stacking with ipamorelin spread widely online but were never validated in controlled trials. They may reflect real user experience, but they carry no more weight than one person's report, and dosing errors from unverified sources carry real risk.

Sources

1. FDA, Drugs@FDA database: No FDA-approved new drug application exists for CJC-1295; approved GH products like Genotropin and Norditropin are listed here instead
2. Journal of Clinical Endocrinology & Metabolism, Teichman et al. 2005: CJC-1295 with DAC half-life of approximately 5.8 to 8.1 days and sustained GH/IGF-1 elevation after single and repeated dosing
3. FDA, Human Drug Compounding Section 503A: Traditional compounding pharmacies operate under Section 503A of the FDCA for patient-specific prescriptions
4. FDA, Outsourcing Facilities under Section 503B: 503B outsourcing facilities must register with FDA and are listed publicly, subject to cGMP and inspection
5. FDA, Warning Letters to compounding pharmacies on GHRH/GHRP peptides, 2023: FDA states GHRH-analogue and GHRP peptides including CJC-1295 and ipamorelin lack adequate basis for legal compounding under 503A/503B
6. NIH StatPearls, Growth Hormone Releasing Hormone physiology: Native GHRH has a short circulating half-life of only a few minutes, context for the no-DAC CJC-1295 analog's short half-life
7. European Journal of Endocrinology, Raun et al. 1998, ipamorelin characterization: Ipamorelin acts as a selective ghrelin-receptor GH secretagogue with minimal effect on cortisol and prolactin compared to older GHRPs
8. NIH, Bowers, growth hormone releasing peptide pharmacology review: GHRH and ghrelin-mimetic secretagogues act on distinct pathways and can produce additive GH release in combination in research settings
9. WADA, 2024 Prohibited List: Growth hormone releasing factors including GHRH analogs are listed as prohibited under class S2 of the WADA Prohibited List